These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Culy CR; Spencer CM Drugs; 2001; 61(5):641-84. PubMed ID: 11368288 [TBL] [Abstract][Full Text] [Related]
68. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Weiss JF Environ Health Perspect; 1997 Dec; 105 Suppl 6(Suppl 6):1473-8. PubMed ID: 9467066 [TBL] [Abstract][Full Text] [Related]
69. Amifostine for protection from antineoplastic drug toxicity. Foster-Nora JA; Siden R Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346 [TBL] [Abstract][Full Text] [Related]
70. [The cytoprotective agent amifostine (WR-2721): current clinical use and trends in its development]. Dragojević-Simić V; Dobrić S Vojnosanit Pregl; 1996; 53(4):305-10. PubMed ID: 9229947 [No Abstract] [Full Text] [Related]
71. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Castiglione F; Dalla Mola A; Porcile G Tumori; 1999; 85(2):85-91. PubMed ID: 10363072 [TBL] [Abstract][Full Text] [Related]
72. The potential of amifostine: from cytoprotectant to therapeutic agent. Santini V; Giles FJ Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165 [TBL] [Abstract][Full Text] [Related]